GabaB agonists for the treatment of alcohol use disorder

Antonio Mirijello; Fabio Caputo; Gabriele Vassallo; Benjamin Rolland; Claudia Tarli; Antonio Gasbarrini; Giovanni Addolorato

Gaba_B agonists for the treatment of alcohol use disorder

Antonio Mirijello, Fabio Caputo, Gabriele Vassallo, Benjamin Rolland, Claudia Tarli, Antonio Gasbarrini, Giovanni Addolorato

IRCCS Casa Sollievo della Sofferenza

Research output: Contribution to journal › Article › peer-review

Abstract

Almost 10% of the world’s population is affected by alcohol use disorder (AUD). The combination between psychosocial intervention and pharmacological treatment seems to be the most effective approach for patients affected by AUD. Among effective drugs useful in the treatment of AUD, GABAB-ergic medications have been tested with encouraging results (i.e. sodium oxybate, baclofen, gabapentin, pregabalin and tiagabine). The present review will summarize available data on these medications.

Original language	English
Pages (from-to)	3367-3372
Number of pages	6
Journal	Current Pharmaceutical Design
Volume	21
Issue number	23
Publication status	Published - Jul 1 2015

Keywords

Alcohol use disorder
Craving
GABA<inf>B</inf> agonists
Pharmacological treatment

ASJC Scopus subject areas

Drug Discovery
Pharmacology

Fingerprint Dive into the research topics of 'Gaba<sub>B</sub> agonists for the treatment of alcohol use disorder'. Together they form a unique fingerprint.

Cite this

@article{b3d40bf3b27b43e2a40077b0a8b7f20a,

title = "GabaB agonists for the treatment of alcohol use disorder",

abstract = "Almost 10% of the world{\textquoteright}s population is affected by alcohol use disorder (AUD). The combination between psychosocial intervention and pharmacological treatment seems to be the most effective approach for patients affected by AUD. Among effective drugs useful in the treatment of AUD, GABAB-ergic medications have been tested with encouraging results (i.e. sodium oxybate, baclofen, gabapentin, pregabalin and tiagabine). The present review will summarize available data on these medications.",

keywords = "Alcohol use disorder, Craving, GABA<inf>B</inf> agonists, Pharmacological treatment",

author = "Antonio Mirijello and Fabio Caputo and Gabriele Vassallo and Benjamin Rolland and Claudia Tarli and Antonio Gasbarrini and Giovanni Addolorato",

year = "2015",

month = jul,

day = "1",

language = "English",

volume = "21",

pages = "3367--3372",

journal = "Current Pharmaceutical Design",

issn = "1381-6128",

publisher = "Bentham Science Publishers B.V.",

number = "23",

}

TY - JOUR

T1 - GabaB agonists for the treatment of alcohol use disorder

AU - Mirijello, Antonio

AU - Caputo, Fabio

AU - Vassallo, Gabriele

AU - Rolland, Benjamin

AU - Tarli, Claudia

AU - Gasbarrini, Antonio

AU - Addolorato, Giovanni

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Almost 10% of the world’s population is affected by alcohol use disorder (AUD). The combination between psychosocial intervention and pharmacological treatment seems to be the most effective approach for patients affected by AUD. Among effective drugs useful in the treatment of AUD, GABAB-ergic medications have been tested with encouraging results (i.e. sodium oxybate, baclofen, gabapentin, pregabalin and tiagabine). The present review will summarize available data on these medications.

AB - Almost 10% of the world’s population is affected by alcohol use disorder (AUD). The combination between psychosocial intervention and pharmacological treatment seems to be the most effective approach for patients affected by AUD. Among effective drugs useful in the treatment of AUD, GABAB-ergic medications have been tested with encouraging results (i.e. sodium oxybate, baclofen, gabapentin, pregabalin and tiagabine). The present review will summarize available data on these medications.

KW - Alcohol use disorder

KW - Craving

KW - GABA<inf>B</inf> agonists

KW - Pharmacological treatment

UR - http://www.scopus.com/inward/record.url?scp=84938595136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938595136&partnerID=8YFLogxK

M3 - Article

C2 - 26088121

AN - SCOPUS:84938595136

VL - 21

SP - 3367

EP - 3372

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 23

ER -